W
WAVEMAN · COMPANY
SCL · Stepan Co
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

SCL

STEPAN CO
PHARMA & BIOTECH · SOAP, DETERGENTS, CLEANG PREPARATIONS, PERFUMES, COSMETICS · CIK 0000094049
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
124
13F, latest reported quarter
REVENUE GROWTH
+7.0%
XBRL, annual
NET MARGIN
2.0%
CONVERSIONS · 180D
4
codes C/M, not in net · $192.2K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
124 funds added or opened last quarter
more than 73% of Pharma & Biotech
REVENUE
+7.0% year over year
more than 57% of Pharma & Biotech
MARGIN
2.0% net margin
more than 69% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
124 funds added or opened positions in the latest 13F quarter, of 231 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +30.0%
+30.0%12M
-14%+4%+21%+38%2025-092025-102025-122026-032026-052026-072026-09
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 124 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for STEPAN CO in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
STEPAN F QUINN JR
Director
SELL
2025-08-05
3,700.0
$186.8K
STEPAN F QUINN JR
Director
SELL
2025-08-04
6,300.0
$314.7K
Lewis Susan
Director
BUY
2025-02-25
500.0
$31.8K
Kabbes David
VP GC & Secretary
BUY
2024-08-14
1,056.0
$75.4K
STEPAN F QUINN JR
Director
SELL
2024-03-07
200.0
$17.6K
46 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 41 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
3,458,328.0 sh
$192.7M
HighTower Advisors, LLC
1,589,877.0 sh
$88.6M
VANGUARD PORTFOLIO MANAGEMENT LLC
1,381,590.0 sh
$77.0M
DIMENSIONAL FUND ADVISORS LP
1,125,025.0 sh
$62.7M
VANGUARD CAPITAL MANAGEMENT LLC
949,949.0 sh
$52.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
SouthernSun Small Cap Fund
$8.6M POSITION · AS OF 2026-03-31
3.6%
DEAN SMALL CAP VALUE
$4.1M POSITION · AS OF 2026-03-31
2.4%
Towle Value ETF
$1.8M POSITION · AS OF 2026-02-27
2.0%
Invesco S&P SmallCap Materials ETF
$224.2K POSITION · AS OF 2026-02-28
1.2%
Virtus Real Asset Income ETF
$200.1K POSITION · AS OF 2026-04-30
1.1%
ProShares Russell 2000 Dividend Growers ETF
$6.7M POSITION · AS OF 2026-02-28
1.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$2.3B$2.2B$2.3B$2.8B
GROSS PROFIT$269.9M$272.2M$277.6M$427.1M
OPERATING INCOME$78.5M$70.5M$58.6M$207.3M
NET INCOME$46.9M$50.4M$40.2M$147.2M
EPS (DILUTED)2.052.201.756.38
OPERATING CASH FLOW$147.9M$162.1M$174.9M$160.8M
CASH$132.7M$99.7M$129.8M$173.8M
LONG-TERM DEBT$341.0M$332.6M$401.2M$455.0M
BUYBACKS$24.9M
DIVIDENDS PAID$35.0M$34.0M$32.9M$30.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →